Santhera Pharmaceuticals Holding Stock Probability of Future Pink Sheet Price Finishing Under 1.93
| SPHDF Stock | USD 9.42 0.00 0.00% |
Santhera |
Santhera Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Santhera Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Santhera Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Santhera Pharmaceuticals generated a negative expected return over the last 90 days | |
| Santhera Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Santhera Pharmaceuticals Holding has accumulated 25.8 M in total debt. Santhera Pharmaceuticals has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Santhera Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Santhera Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Santhera Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Santhera to invest in growth at high rates of return. When we think about Santhera Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (55.53 M) with loss before overhead, payroll, taxes, and interest of (5.36 M). | |
| Santhera Pharmaceuticals Holding has accumulated about 21.21 M in cash with (37.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.43. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
Santhera Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Santhera Pink Sheet often depends not only on the future outlook of the current and potential Santhera Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Santhera Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 49.6 M |
Santhera Pharmaceuticals Technical Analysis
Santhera Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Santhera Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Santhera Pharmaceuticals Holding. In general, you should focus on analyzing Santhera Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Santhera Pharmaceuticals Predictive Forecast Models
Santhera Pharmaceuticals' time-series forecasting models is one of many Santhera Pharmaceuticals' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Santhera Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Santhera Pharmaceuticals
Checking the ongoing alerts about Santhera Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Santhera Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Santhera Pharmaceuticals generated a negative expected return over the last 90 days | |
| Santhera Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Santhera Pharmaceuticals Holding has accumulated 25.8 M in total debt. Santhera Pharmaceuticals has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Santhera Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Santhera Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Santhera Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Santhera to invest in growth at high rates of return. When we think about Santhera Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (55.53 M) with loss before overhead, payroll, taxes, and interest of (5.36 M). | |
| Santhera Pharmaceuticals Holding has accumulated about 21.21 M in cash with (37.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.43. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
Other Information on Investing in Santhera Pink Sheet
Santhera Pharmaceuticals financial ratios help investors to determine whether Santhera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santhera with respect to the benefits of owning Santhera Pharmaceuticals security.